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We conducted a retrospective case-control study of children attending the Yale-
New Haven Hospital Premature Infant Primary Care Clinic (YNHH-PIPCC). Subjects 
were prematurely born children under 24 months of age cared for at the YNHH-PIPCC 
between October 2000 and March 2011. They are eligible to receive monthly passive 
respiratory syncytial virus (RSV) immunization with palivizumab during the RSV 
season. All cases had laboratory-documented severe RSV disease necessitating hospital 
admission or outpatient visit. Controls did not have severe RSV disease during the same 
season as their matched case. Controls were matched to the cases by gestational age and 
month of birth. Risk of severe RSV disease was estimated using matched ORs and 
adjusted for potential confounders with the use of conditional logistic regression. The 
hypothesis of this study is that receiving less than all expected doses of palivizumab 
reduces the effectiveness of palivizumab in preventing severe RSV disease. Of 299 
eligible subjects identified during the study’s 11 RSV seasons (October 2000 through 
March 2011), 28 (9%) experienced RSV infections. Of the 28 subjects with RSV 
infection, 24 (85.7%) subjects were adherent to the dosing protocol. Severe RSV disease 
requiring hospital admission was noted in 15 of 217 (7%) of adherent subjects compared 
with 3 of 72 (4%) of non-adherent subjects. Cases of severe RSV disease were more 
likely to be Hispanic (61% vs. 39%; p-value: 0.05) than matched controls. There was no 
association between adherence to the dosing protocol and hospital admission due to 
severe RSV disease. These findings suggest the need for further study of palivizumab 
dosing recommendations and factors that may be influencing adverse health events in 
premature Hispanic children receiving health care at the YNHH-PIPCC.   




  Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract 
morbidity, especially bronchiolitis and pneumonia in children under two years of age. In 
the United States, approximately 75,000—125,000 RSV-related infant hospitalizations 
occur annually [1]. Annual epidemics of RSV infection occur over a 5-month season 
from November through March in temperate climates. Seasonality is a significant factor 
in determining the risk of infection. Although RSV infects people of all ages, children 
under two years of age are particularly susceptible. Risk factors of severe RSV infection 
include preterm birth, chronic lung disease, congenital heart disease, immunodeficiency, 
and receipt of immunosuppressive therapy [2]. 
 Premature infants are at high risk for severe RSV infection that often requires 
hospitalization. Although there is no existing active immunization for the prevention of 
RSV infection, passive immunization with palivizumab (Synagis), a humanized 
monoclonal antibody that binds the F-protein of RSV, has been shown to reduce the risk 
of RSV hospitalization from 39% to 78% among high-risk infants, depending on the 
subsets of the study sample [3]. There was a 39% reduction in RSV hospitalization in 
premature infants with bronchopulmonary dysplasia and a 78% reduction in premature 
infants with no bronchopulmonary dysplasia. A monthly injection of palivizumab is 
recommended to protect high-risk infants throughout the months of each RSV season [4]. 
The price of a full 5-dose regimen can exceed $8000 (average wholesale price), 
depending on the recipient’s body weight [5]. Due to its cost, palivizumab is limited in its 
administration to populations at the highest risk for severe RSV illness. 
 Monthly doses of palivizumab are recommended to maintain a threshold serum 
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concentration of anti-RSV antibody, the rationale for which is based largely on previous 
studies of palivizumab [3]. These have examined cost-effectiveness of palivizumab 
prophylaxis, adherence to monthly palivizumab prophylactic guidelines, and the efficacy 
of compliance at reducing RSV infection-related hospitalization in high-risk infants [3, 6-
9]. Little data is available, however, on quantifying the risk of RSV disease in high-risk 
patients when they miss monthly doses of palivizumab.  
 The proposed study aims to evaluate whether incomplete monthly palivizumab 
dosing regimens lead to decreased protection from severe RSV disease (i.e. RSV 
infection necessitating hospitalization or a hospital outpatient visit) compared with 
complete dosing regimens. An incomplete dosing regimen in a premature infant is 
defined as one where an infant did not receive all expected palivizumab doses at the time 
of a scheduled monthly outpatient visit to the Yale-New Haven Hospital Premature Infant 
Primary Care Clinic (YNHH-PIPCC). 
Previous studies in premature infants have shown that a complete palivizumab 
course offers a reduced risk of hospitalization due to RSV infection of 55% [3], whereas 
an incomplete regimen was associated with a significantly higher proportion of 
hospitalizations [9]. Accordingly, the hypothesis of this study is an incomplete 
palivizumab regimen due to missed doses reduces the effectiveness of palivizumab in 
preventing hospitalization due to RSV infection. Such a finding could warrant a re-
evaluation of the efficiency and cost-effectiveness of current palivizumab dosing 
recommendations in high-risk premature infants. 
 
 





 We conducted a retrospective case-control medical record review of premature 
infants attending the YNHH-PIPCC. Study subjects were premature children who were 
cared for at the YNHH-PIPCC between October 2000 and March 2011 and who were 
eligible to receive palivizumab according to Pediatric Red Book guidelines. 
 Study subjects were identified from YNHH-PIPCC database, which contained 
names, medical record numbers, and birth dates for all palivizumab eligible patients from 
October 2000 through March 2011, a total of eleven RSV seasons. 
 Case subjects were children under 24 months of age cared for at the YNHH-PIPCC 
who were palivizumab eligible (according to Pediatric Red Book guidelines) and were 
admitted to the hospital as an inpatient or as an Emergency Department visit due to RSV 
infection during the 2000 to 2011 RSV seasons. 
 Control subjects were children less than 24 months of age cared for at the YNHH-
PIPCC who were palivizumab eligible (according to Pediatric Red Book guidelines), but 
who did not have RSV disease during the same season as their matched case. Controls 
were matched to cases by gestational age (±2 weeks from the gestational age of the case) 
and season of birth (±1 month of the birth month of the case). The controls were matched 
to cases systematically so that preference was given to controls that were within one 
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Data Collection  
Clinical and demographic data for study subjects were obtained from YNHH’s 
electronic medical record systems Sunrise Clinical Manager and Logician, including 
laboratory data on RSV results from specimens submitted to the clinical virology 
laboratory. 
Demographic and clinical data included date of birth, race, gender, gestational 
age, birth weight, intubation at birth, hospital length of stay after birth, underlying 
conditions (congenital heart disease, chronic lung disease, HIV), palivizumab 
administration dates, RSV infection dates, and hospital length of stay for RSV infection. 
Study personnel created a standardized medical record review form to abstract data from 
each subject’s medical record. All information was then entered into Microsoft Access 
2007. 
 According to the American Academy of Pediatrics’ Red Book (2009), indications 
for palivizumab eligibility specify that a maximum of 5 monthly doses may be 
administered to children younger than 24 months of age with congenital heart disease, 
chronic lung disease of prematurity, or a preterm birth at less than 32 weeks gestation. 
The protocol recommends that strict adherence to monthly administration be maintained. 
 Adherence, based strictly on the dosing recommendations, was defined as follows: 
Depending on the month of birth, the child received all expected doses and did not miss a 
monthly dose. For example, if the first dose was given in December, then it was expected 
that the child received four doses through March. Subjects not receiving a full 
palivizumab course were categorized as non-adherent. Cases and controls were stratified 
by adherence according to whether they received complete dose regimens (received all 
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expected doses) or incomplete dose regimens (did not received all expected doses). 
Data Analysis 
The number of doses of palivizumab received by cases and controls was assessed 
through medical record review. Data for palivizumab was stratified by number of doses 
received, distinguishing between those who received a complete dose regimen—the 
infant received a monthly dose throughout the RSV season—or an incomplete dose 
regimen—the infant failed to receive one or more expected monthly doses during the 
RSV season. Bivariate analysis using a χ2 test of association was used to examine 
associations between subject characteristics and RSV disease status. The risk of severe 
RSV disease was estimated directly from matched odds ratios. Conditional logistic 
regression was used to adjust for potential confounders. Matched odds ratios measuring 
the association of risk factors and RSV infection were calculated with logistic regression 
in SAS version 9.2. Tests were conducted at the α level of 0.05 for statistical significance. 
P-values equal to or less than 0.05 were considered significant.  
Ethical Approval 












A total of 299 study eligible subjects were identified between October 2000 and  
March 2011. Overall, 28 (9.4%) RSV infections were identified during the 11 RSV 
seasons. Infections occurred during months of October through April, with a majority of 
the infections occurring from December through February (Figure 1).  
 
 
This distribution of infections follows the typical pattern of RSV infection in temperate  
climates as defined in CDC surveillance reports. Of the 28 infections, 18 (64%) resulted 
in hospitalization and 10 (36%) ED visits or clinic visits. Subject characteristics are 
shown in Table 1. The majority of children were Black (59.9%) or Hispanic (32.8%). 
Overall, 95% had received at least one dose of palivizumab and 226 (75.6%) were found 
to be adherent to the dosing protocol. Of the 28 subjects with RSV infection, 24 (85.7%) 
subjects were adherent to the dosing protocol. Severe RSV disease requiring hospital 






























Total RSV Infections in Sample 
2000-2011 
Figure 1. RSV infections by month from October 2000 - March 2011 
in the study sample. 
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of non-adherent subjects. This difference was not statistically different (p-value: 0.19). 
Ethnicity and congenital heart disease were the only characterizing variables that were 
statistically significant in explaining an association with RSV infection (Table 1).  
 














ᶲIncluded: Hemodynamically significant cyanotic or acyanotic congenital heart disease, atrial 
septal defect, ventricular septal defect, peripheral pulmonary stenosis, patent ductus arteriosus. 
*Definition of adherence: Depending on the month of birth, the child received all expected doses 




Characteristic RSV+ n = 28 (%) 
RSV- 
n = 271 (%) p 
Race/ethnicity   0.02 
     White     0   (0)      16   (6)  
     Black   13 (46)    166 (61)  
     Hispanic   13 (46)      85 (31)  
     Asian     1   (4)        0   (0)  
     Other     1   (4)        4   (2)  
 
Sex   
 
0.58 
     Male   16 (57)    140 (52)  
     Female   12 (43)    131 (48)  
 
Mechanical Intubation   
 
0.14 
     Yes     4 (14)      18   (7)  
     No   24 (86)    253 (93)  
 
Chronic Lung Disease†   
 
0.47 
     Yes   13 (46)    107 (39)  
     No   15 (54)    164 (61)  
 
Congenital Heart Disease   
 
0.01 
     Yes     8 (29)      32 (12)  
     No   20 (71)    239 (88)  
 
Non-adherent to dosing protocol*   
 
0.19 
     Yes     4 (14)      69 (25)  
     No   24 (86)    202 (75)  
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To assess if there were any predictors of non-adherence, non-adherent subjects 
were compared with subject characteristics (Table 2). There were no differences in 
adherence to dosing for any subject characteristics.  
 
Table 2. Associations between subject characteristics and nonadherent subjects. 
ᶲIncluded: Hemodynamically significant cyanotic or acyanotic congenital heart disease, atrial 
septal defect, ventricular septal defect, peripheral pulmonary stenosis, patent ductus arteriosus. 
*Definition of adherence: Depending on the month of birth, the child received all expected doses 






Characteristic Cases n = 18 
Controls 
n = 271 N 
 Nonadherent* 
N (%) p 
Race/ethnicity     0.52 
     White 0      16     16   5 (31)  
     Black 6    166   172 45 (26)  
     Hispanic        11      85     96 22 (23)  
     Asian 0 0 1          0  
     Other 1 4 5          0  
 
Sex     0.42 
     Male 8    131   139 42 (30)  
     Female        10    140   150 30 (20)  
 
Mechanical Intubation     0.35 
     Yes 4      18     22   7 (32)  
     No        14    253   267 65 (24)  
 
Chronic Lung Disease     0.40 
     Yes 8    107   115 29 (25)  




    0.52 
     Yes 6      32     38   6 (16)  
     No        12    239   251 66 (26)  
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Characteristics of cases and controls are shown in Table 3. Of the 299 subjects, a 
total of 289 were eligible for the matched analysis. The ten ineligible controls did not 
meet matching criteria for gestational age (±2 weeks from the gestational age of the case) 
and seasonality of birth (±1 month of the birth month of the case). Cases of RSV were 
more likely to be Hispanic (61% vs. 39%; p-value: 0.05) than their matched controls. We 
examined the risk of RSV hospitalization for all other race combinations, but did not find 
any significant predictors of cases based on these other race combinations.   
Table 3. Characteristics of cases and controls. 
Characteristic Cases n = 18 (%) 
Controls 
n = 271 (%) 
Matched OR  
(95% CI) p 
Race/ethnicity     
     All other races     7 (39) 186 (69)             Reference  
     Hispanic   11 (61)   85 (31) 3.46 (1.02, 11.80) 0.05 
 
Sex    
 
     Female     8 (56) 131 (48) Reference  
     Male   10 (44) 140 (52) 1.10 (0.41, 2.91) 0.85 
 
Mechanical Intubation    
 
     No   14 (78) 253 (93) Reference  
     Yes     4 (22)      18   (7) 3.43 (0.67, 17.69) 0.14 
 
Chronic Lung Disease    
 
     No   10 (56) 164 (61) Reference  
     Yes     8 (44) 107 (39) 1.40 (0.37, 5.25) 0.61 
 
Congenital Heart Diseaseᶲ    
 
     No   12 (67) 239 (88) Reference  
     Yes     6 (33)   32 (12) 3.71 (0.95, 14.39) 0.06 
 
Non-adherent to dosing protocol*    
 
     No   15 (83) 202 (75) Reference  
     Yes     3 (17)   69 (25) 0.92 (0.21, 4.08) 0.91 
ᶲIncluded: Hemodynamically significant cyanotic or acyanotic congenital heart disease, atrial 
septal defect, ventricular septal defect, peripheral pulmonary stenosis, patent ductus arteriosus. 
*Definition of adherence: Depending on the month of birth, the child received all expected doses 
and did not miss a monthly dose. 
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Matched odds ratios of the association between ethnicity and non-adherence with 
hospitalization due to RSV infection are shown in Table 4. When we controlled for 
potential confounders, Hispanic subjects continued to be at increased risk of 
hospitalization when compared with all other races (OR: 3.47; 95% CI: 1.01-11.84; p -
value: 0.05). However, we did not find an association between adherence to the dosing 
protocol, defined as receiving all expected doses during an RSV season, and 
hospitalization due to RSV infection. Non-adherent subjects were no more likely than 
adherent subjects to be cases.  
Table 4. Multivariate logistic regression model of characteristics associated with hospitalization 
due to respiratory syncytial virus infection (N = 289). 
Characteristic Cases  n = 18 (%) 
Controls  
n = 271 (%) 
Matched OR 
(95% CI) p 
Race/ethnicity     
     All other races   7 (39) 186 (69)    Reference --- 
     Hispanic 11 (61)   85 (31)    3.47 (1.01, 11.84) 0.05 
     
Non-adherent to dosing protocol*     
     No 15 (83) 202 (75)    Reference --- 
     Yes   3 (17)   69 (25)    1.02 (0.23,   4.50) 0.98 
*Definition of adherence: Depending on the month of birth, the child received all expected doses 
and did not miss a monthly dose. 
 
 
In the bivariate analysis, the test association between Hispanic ethnicity and study 
characteristics identified two statistically significant associations. First, being Hispanic 
was associated with having congenital heart disease (p-value: 0.03). Additionally, being 















This case-control study examines the risk of severe RSV disease due to a failure 
in receiving all expected palivizumab doses during an RSV season. Non-adherence to the 
recommended dosing protocol, defined as failing to receive all expected doses throughout 
an RSV season, was found to have no association with hospitalization due to RSV 
infection. Hispanic children were found to be at increased risk for hospitalization due to 
RSV infection (OR: 3.47, 95% CI: 1.01-11.84) when controlling for potential 
confounders. Based on these results, efforts to maintain complete adherence to the dosing 
protocol may not be necessary. Missing one of the expected doses during the RSV season 
may not put a child at increased risk of RSV hospitalization. Optimal palivizumab dosing 
for the prevention of RSV infection must take into account the increased risk of severe 
RSV disease in Hispanic children.  
The lack of a significant association between missing one or more doses of 
palivizumab and being hospitalized due to RSV infection may be partially explained by 
palivizumab titer in children who received the drug. Monthly doses of palivizumab are 
recommended to maintain a threshold serum concentration of anti-RSV antibody. The 
target for threshold serum concentration is 40 µg/ml, which was derived from preclinical 
data in rats. Rats maintaining levels greater than this threshold showed a 99% reduction 
in pulmonary RSV. The IMpact RSV-Group reported data on serum concentration of 
palivizumab in premature infants as part of the palivizumab approval study [3]. The data 
suggest the trend of a cumulative effect of serum concentration through monthly dosing 
at 15mg/kg concentration. If a child missed one dose but maintained a serum 
concentration level above the threshold level of anti-RSV antibody, then the child may 
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still be protected against viral insult. Another possibility is that children who were 
adherent were at higher risk for severe disease than children who were non-adherent due 
to factors that were not detected in our analysis.  
An interesting finding in the current study was that Hispanic children were more 
likely to have congenital heart disease and more likely to be hospitalized with severe 
RSV disease when compared with all other ethnicities. Although congenital heart disease 
was not found to be associated with RSV hospitalization, the increased risk of congenital 
heart disease in Hispanics may be a factor in explaining the high proportion of RSV 
hospitalization among this group of children. 
This study was not without limitations. Subjects were enrolled from a single 
healthcare center, so there was a relatively small sample size with only 28 subjects 
infected with RSV and 18 hospitalizations due to RSV in 11 seasons. However, study 
personnel were able to capture all eligible children who attended the YNHH-PIPCC. 
Additionally, data on palivizumab administration for children at YNHH was thoroughly 
recorded from the first RSV season that the drug was administered. YNHH-PIPCC 
consistently administered palivizumab, as can be seen in the high proportion (75%) of 
children receiving a full course of the prophylactic drug. This may partially explain the 
low number of RSV infections in the sample.  
Palivizumab was developed to prevent RSV infection, not necessarily to prevent 
RSV hospitalization. The reported results restricted the analysis to children hospitalized 
with RSV disease (n=18). However, including all 28 RSV-infected children in the 
analysis did not significantly change results. Limiting cases to children hospitalized with 
RSV infection was necessary to capture only severe RSV infections. Because children 
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may have acquired RSV infection without seeking or acquiring medical care, estimated 
associations between RSV infection and characteristics of subjects would have been 
biased had we not separated the most severe RSV cases from the controls.  
 The findings of this study prompt a continued investigation of the effectiveness of 
palivizumab dosing recommendations. Capturing more cases by expansion to additional 
study sites is necessary to improve precision in identifying associations between subject 
characteristics and clinical outcomes. With these additional data, palivizumab-eligible 
children can be stratified based on every dose received. The effectiveness of each dose 
can be directly estimated. Furthermore, a greater distribution of the ethnicities enrolled in 
this study would be beneficial for comparing risk factors for severe RSV disease. To 
examine if palivizumab titer influences the risk of RSV infection, a laboratory component 
could be designed to measure serum concentrations for infants receiving palivizumab. 
This information could be related to the risk of RSV infection among adherent and non-
adherent dosing groups receiving various numbers of doses throughout an RSV season.  
 Preterm children are at increased risk of respiratory syncytial virus infection. This 
retrospective study shows palivizumab dosing adherence over 11 RSV seasons at the 
Yale-New Haven Hospital Premature Infant Primary Care Clinic and relates it to the risk 
of hospitalization due to RSV. No association was found between RSV hospitalization 
and dosing adherence. However, Hispanic children were found to be at increased risk of 
RSV hospitalization and congenital heart disease. This finding should prompt further 
exploration of factors that may be influencing adverse health events in Hispanic preterm 
infants receiving health care at the Yale-New Haven Hospital Premature Infant Primary 
Care Clinic.  
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